Letters, Testimony & Comments

Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written...
April 29 2014
November 6, 2013 The Honorable Robert Menendez 528 Hart Senate Office Building United States Senate Washington, D.C....
November 6 2013
Kenneth I. Moch President and Chief Executive Officer, Chimerix, Inc. On behalf of the Biotechnology Industry Organization Before the...
July 10 2013
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
July 26 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 16 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
March 6 2012
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
December 1 2011
Good morning Chairman Casey, Vice Chairman Brady, Ranking Member DeMint, Ranking Member Hinchey, Members of the Committee, ladies, and...
May 25 2011
Dear Chairman Frelinghuysen and Ranking Member Visclosky: On behalf of the Biotechnology Industry Organization (BIO), I am writing to...
May 17 2011
Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman...
April 7 2011
Re: Request for Comments on the Strategy for American Innovation Subject: Innovation Strategy RFI Email: competitiveness@doc.gov Dear...
April 1 2011
SECTION 1. PURPOSE This notice establishes the qualifying therapeutic discovery project program under § 48D of the Internal...
August 3 2010
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for...
August 3 2010
A letter to the House Ways & Means Committee by 54 trade organizations and companies supporting the extension of cellulosic biofuel...
June 23 2010
Dear Chairman Inouye and Ranking Member Cochran: As the Senate debates fiscal year 2011 federal funding, the undersigned organizations...
June 1 2010
Access to Early Capital In the United States and globally, commercial development of biotechnology relies on the continuing...
May 27 2010
BIO and 34 companies and trade organizations sent a letter to Chairman Levin and Ranking Member Camp, of the House Ways and Means...
May 17 2010
Dear Ms. Blue, This letter is submitted by the Biotechnology Industry Organization (BIO) in response to the request for public comment...
November 3 2009
Good morning Chairwoman Velázquez, Ranking Member Graves, Members of the Committee, the Staff of the Committee, ladies and...
October 14 2009
Good morning Chairman Wu, Ranking Member Smith, Members of the Committee, ladies and gentleman. I am Jim Greenwood, President and CEO of...
April 23 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 20 2009
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO...
October 27 2008
Dear Chairman Cox and Director Thomsen: On behalf of its members, the Biotechnology Industry Organization (“BIO”) would...
September 22 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
The Biotechnology Industry Organization (BIO) appreciates this opportunity tp provide the perspective of its members on the Bayh-Dole Act...
August 27 2007
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
Administrator, U.S. Small Business Administration
May 13 2003
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies....
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section...
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

April 29 2016
Bill would enhance the voice of emerging companies at the SEC Washington, D.C. (April 29, 2016) – Today, the Biotechnology Innovation Organization (BIO) applauds Senators Heidi Heitkamp (D-ND), Dean Heller (R-NV) and Gary Peters (D-MI) for introducing the SEC Small Business Advocate Act, which would ensure that growing companies have a strong, independent voice at the Securities and Exchange Commission (SEC). 
February 9 2016
Elements of the President’s budget proposal for 2017 directly threaten his Administration’s goal of curing cancer through advances in precision medicine
February 2 2016
BIO applauds the House of Representatives for approving the SEC Small Business Advocate Act (H.R. 3784) and the Small Business Capital Formation Enhancement Act (H.R. 4168). These bills would enhance the role that small businesses play in the decision-making process at the Securities and Exchange Commission, ensuring that SEC policies support the growth of emerging biotech innovators.
December 16 2015
BIO today welcomed legislation to extend critical tax incentives that are important to biotechnology companies. The legislation would make permanent the important Research & Development Tax Credit.
December 2 2015
BIO supports legislation to follow up on the success of the JOBS Act